View Older Stories View More Recent Stories
-
Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche
-
Weight-loss drug pioneers aim to jump on Wegovy bandwagon
-
Weight-loss drug pioneers aim to jump on Wegovy bandwagon
-
Weight-loss drug pioneers aim to jump on Wegovy bandwagon
-
Weight-loss drug pioneers aim to jump on Wegovy bandwagon
-
Weight-loss drug pioneers aim to jump on Wegovy bandwagon
-
Weight-loss drug pioneers aim to jump on Wegovy bandwagon
-
Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems
-
Be Biopharma Announces Oral Presentation on Precise Genome Engineering of Human B Cells to Express Diverse Therapeutic Proteins at American Society of Gene & Cell Therapy 26th Annual Meeting
-
Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncoge
-
Form SC 13G/A ARYA Sciences Acquisitio Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A DA32 Life Science Tech Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Travere Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Adela Announces Appointment of Alan Williams as Chief Operating Officer
-
MBX Biosciences to Participate in May Investor Conferences
-
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors
-
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
-
Be Biopharma Announces First Scientific Disclosures and New Preclinical Data Supporting the Advancement of B Cell Medicines at the American Society of Gene & Cell Therapy 26th Annual Meeting
-
Form SC 13D/A Satsuma Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cortica Closes $75 Million in New Funding Round and Acquires Springtide Child Development
-
Ocelot Bio Appoints Lise Kjems, M.D., Ph.D., as Chief Medical Officer
-
Adela presents data demonstrating strong detection of 12 cancer types at the American Association for Cancer Research Annual Meeting 2023
-
Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
-
Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1
-
Novo Holdings invests in US$105 million Series C Funding of Alentis Therapeutics
-
Form SC 13G NanoString Technologies Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, L.P.
-
MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
-
Over DKK 3 billion (USD 413 million) raised by BioInnovation Institute portfolio companies to date
-
Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline
-
Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
-
Form SC 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.

